Sanofi (NASDAQ:SNY) Shares Bought by National Bank of Canada FI

National Bank of Canada FI raised its position in Sanofi (NASDAQ:SNY - Free Report) by 2.0% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 303,934 shares of the company's stock after purchasing an additional 6,089 shares during the period. National Bank of Canada FI's holdings in Sanofi were worth $14,659,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Raymond James Financial Inc. acquired a new stake in shares of Sanofi in the fourth quarter valued at approximately $135,933,000. Boston Partners grew its holdings in Sanofi by 86.4% during the 4th quarter. Boston Partners now owns 5,396,531 shares of the company's stock valued at $260,607,000 after buying an additional 2,501,073 shares during the last quarter. Magnetar Financial LLC raised its holdings in shares of Sanofi by 104.3% in the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock worth $161,103,000 after acquiring an additional 1,705,148 shares during the last quarter. DAVENPORT & Co LLC lifted its position in shares of Sanofi by 40.7% in the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company's stock valued at $110,715,000 after acquiring an additional 664,455 shares in the last quarter. Finally, Thrivent Financial for Lutherans boosted its stake in shares of Sanofi by 36.0% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,943,761 shares of the company's stock valued at $93,774,000 after acquiring an additional 514,542 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on SNY. The Goldman Sachs Group started coverage on shares of Sanofi in a research report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective for the company. StockNews.com downgraded Sanofi from a "buy" rating to a "hold" rating in a research report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi has a consensus rating of "Moderate Buy" and an average price target of $62.50.

Sanofi Stock Down 4.4 %

Shares of Sanofi stock traded down $2.27 during trading hours on Thursday, hitting $48.94. 1,024,264 shares of the company's stock traded hands, compared to its average volume of 2,312,845. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12. The company has a market cap of $123.64 billion, a PE ratio of 19.66, a PEG ratio of 1.01 and a beta of 0.57. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The stock has a 50 day simple moving average of $55.08 and a 200-day simple moving average of $52.47.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Equities research analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.